Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥294.00 - ¥723.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥6.53B
Enterprise Value¥1.41B
Total Cash (Recent Filing)¥4.79B
Total Debt (Recent Filing)¥25.26M
Price to Earnings (P/E)91.0
Beta0.87
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)3.56
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.79
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5
Revenue Forecast (FY)¥3.70B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal leverage and a conservative balance sheet provide durable financial flexibility for a biotech firm. Low debt reduces refinancing and interest coverage risk, supports R&D spending or strategic investments during downturns, and improves resilience over the next 2–6 months.
Consistent Positive Cash GenerationSustained positive operating and free cash flow supports internal funding of development and operations without reliance on frequent external financing. Even with volatility, persistent cash generation gives the company more control over capital allocation and resilience over the medium term.
Healthy Gross MarginA still-healthy gross margin signals that core product economics or service pricing retain strength. If fixed costs and operating leverage are managed, underlying gross profitability can help margins recover, supporting sustainable earnings improvement over several quarters.
Bears Say
Collapsed Returns On EquityA sharp collapse in ROE reflects a structural deterioration in the company’s ability to turn capital into earnings. Persistently weak returns constrain reinvestment capability and shareholder value creation, and may require strategic shifts or capital restructuring to restore long-term profitability.
Near-Break-Even Net MarginsNet margins sliding to near zero indicate material operating or cost pressures that undermine free cash generation. Over a multi-quarter horizon, this reduces the company’s buffer against shocks and limits capacity to scale R&D or commercial initiatives without improving cost structure or revenue mix.
Weakened Cash Quality And VolatilityMixed cash conversion and a year where operating cash flow failed to cover earnings point to declining cash quality. For a biotech company, volatile FCF raises funding uncertainty for trials and commercialization, increasing likelihood of external financing or cutbacks if trends persist.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥294.00 and its highest was ¥723.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.53B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Sep 10, 2026 which is in 47 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥1.89 earnings per share for the quarter, beating the consensus estimate of N/A by ¥1.89.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.54%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.89 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.631%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―